<code id='AA67C6AC59'></code><style id='AA67C6AC59'></style>
    • <acronym id='AA67C6AC59'></acronym>
      <center id='AA67C6AC59'><center id='AA67C6AC59'><tfoot id='AA67C6AC59'></tfoot></center><abbr id='AA67C6AC59'><dir id='AA67C6AC59'><tfoot id='AA67C6AC59'></tfoot><noframes id='AA67C6AC59'>

    • <optgroup id='AA67C6AC59'><strike id='AA67C6AC59'><sup id='AA67C6AC59'></sup></strike><code id='AA67C6AC59'></code></optgroup>
        1. <b id='AA67C6AC59'><label id='AA67C6AC59'><select id='AA67C6AC59'><dt id='AA67C6AC59'><span id='AA67C6AC59'></span></dt></select></label></b><u id='AA67C6AC59'></u>
          <i id='AA67C6AC59'><strike id='AA67C6AC59'><tt id='AA67C6AC59'><pre id='AA67C6AC59'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:Wikipedia    Page View:1198
          Astrida Schaeffer
          Since February 2022, Astrida Schaeffer has driven about 160 miles round trip every other week to Brigham and Women’s Hospital in Boston, where researchers are testing an intravenous drug they hope will prevent the onset of Alzheimer’s disease symptoms, or at least delay them. Suzanne Kreiter/The Boston Globe

          Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations, leaving her feeling helpless and bereft.

          The first was her Polish-born maternal grandmother, who began showing symptoms when Schaeffer started college in 1981 and died seven years later. Then came her mother, a onetime Fulbright Scholar and high school language teacher who had been fluent in five languages but lost the ability to speak. She died in 2019. Last year, the disease killed Schaeffer’s mother’s sister, a former lab technician for Johnson & Johnson.

          advertisement

          Schaeffer, a 59-year-old costume historian in North Berwick, Maine, has no symptoms of Alzheimer’s. But in 2021 her family history led her to apply to join a clinical trial testing a drug on people at risk for developing them. To participate, volunteers couldn’t have cognitive impairment. But they needed to test positive for a biomarker that put them at higher risk for mental decline ― deposits of a sticky toxic protein in the brain called beta-amyloid that is a hallmark of the disease.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          House panel to mark up pandemic
          House panel to mark up pandemic

          HouseEnergy&CommerceChairCathyMcMorrisRodgers(R-Wash.)KevinDietsch/GettyImagesWASHINGTON—AHouses

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Neutralizing antibodies against HIV shows promise in children

          BuddingHIVvirions.NIAID/NIHWhenchildrenlivingwithHIVareinjectedwithneutralizingantibodies,thetreatme